Results 281 to 290 of about 151,502 (357)

Impact of Early‐Line Systemic Therapies on Liver Function in Hepatocellular Carcinoma: Longitudinal Change of ALBI Score and Ammonia Level With and Without Anti‐VEGF Agents

Hepatology Research, EarlyView.
ABSTRACT Background and Aim Anti–vascular endothelial growth factor (VEGF) agents are widely used for hepatocellular carcinoma (HCC); inhibition of VEGF‐mediated liver regeneration may compromise hepatic reserve. We investigated the impact of anti‐VEGF therapy on liver function and risk factors for deterioration of albumin–bilirubin (ALBI) score during
Naoshi Nishida, Kazuomi Ueshima, Tomoko Aoki, Takuya Matsubara, Naoya Omaru, Natsuki Okai, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Masatoshi Kudo   +11 more
wiley   +1 more source

Seropositive Myasthenia Gravis Triggered by Lyme Disease: A Case Study of Molecular Mimicry. [PDF]

Cureus
Sardana S, Grieco E, MacGavin S, Shakeel HA, Piccinnin M, Gill TS.   +5 more
europepmc   +1 more source

Efficacy of Hepatitis B vaccine in those who lost Hepatitis B surface antigen during follow-up: Efficacy of HBV vaccine in those who lost HBsAg.

, 2011
Hassan Taheri, Mohammad Reza Hasanjani Roushan, Mohammad Jafar Soleimani Amiri, Mohammad Pouralijan, Ali Bijani   +4 more
openalex   +1 more source

Hepatitis B antigen hepatomas.

Indian journal of medical sciences, 1978
S S, Kelker, V H, Talib, P M, Khare, G G, Menon, B S, Raichur   +4 more
openaire   +1 more source

Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in people previously treated with darunavir‐based antiretroviral therapy

HIV Medicine, EarlyView.
Abstract Background Darunavir‐based antiretroviral therapy (ART) is commonly used in people with HIV who experience adherence challenges and/or have complex resistance patterns. Changes in ART commissioning have led to an increased use of Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in these populations despite limited real‐world outcome ...
Rhianna Sheridan, Yasmin Osei‐Kuffour Ekert, Lucy Campbell, Mark Zuckerman, Sally Hawkins, Kate Childs, Frank A. Post   +6 more
wiley   +1 more source

Liver Safety Assessment of an Indonesian Hexavalent Vaccine Candidate Through Histopathology and ALT/AST Evaluation in Rats and Rabbits. [PDF]

Vaccines (Basel)
Pratiwi ED, Mawaddah TW, Sadjuri AR, Nugroho DT, Hidayat A, Nidom AN, Ayyuba ZI, Wahyuningsih ES, Santoso KP, Plumeriastuti H, Soeharsono, Indrasari S, Nidom RV, Wijayadikusumah AR, Nidom CA.   +14 more
europepmc   +1 more source

Innate Immune Activation Is a Strong Suppressor of CCL22 and Impedes Regulatory T Cell–Dendritic Cell Interaction

Immunology, EarlyView.
During homeostasis, CCL22 is secreted by dendritic cells (DC), which mediate contacts between regulatory T cells (Treg) and DC to maintain immune balance. Activation of innate immunity via microbes or pattern recognition receptor (PRR) agonists induces the secretion of several soluble factors (e.g., type I and II interferons, IL‐10), which mediate ...
Ignazio Piseddu, Jan Gärtig, Stephan Eiber, Stefan Moder, Raffael Thaler, Matthias Thaler, Juliane Gruen, Marlies Vornhülz, Kevin Bahner, Luana Messa, Benjamin Kühnemuth, Jennifer Müller, Konstantin Schnell, Antonia Beimert, Carolin Perleberg, Natascha Röhrle, Maximilian Martin Ludwig Knott, Linda Hammann, Vanessa Wittmann, Patrick Layritz, Moritz Rapp, Carole Bourquin, Julia Mayerle, Stefan Endres, David Anz   +24 more
wiley   +1 more source

Peripheral and intrahepatic B-cell subsets contribute to HBeAg seroconversion in patients with chronic hepatitis B. [PDF]

Virol J
Zuo J, Yang XQ, Zhou FM, Qu ZJ, Tian YX, Yang JR, Fan YC.   +6 more
europepmc   +1 more source

Epidemiology and Genetics of Rheumatic Diseases Suggest a Constant Rate of DNA Damage as Underlying Cause

Immunology, EarlyView.
A constant rate of DNA damage that is not perfectly repaired will cause a constant rate of DNA mutations. The chance of mutation will increase if DNA is prone to damage, such as occurs in somatic hypermutation (SHM) hotspots and GC‐rich DNA. Thus, if one mutation‐prone DNA site drives disease, the age of onset of disease and degree of penetrance should
Piet C. de Groen
wiley   +1 more source

Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial. [PDF]

Gut
Wu X, Quan D, Li W, Wisskirchen K, Wu W, Zhou Y, Liu YP, Wan X, Wang X, Zhang X, Yang L, Zheng M, Zhang K, Protzer U, Du S, Qu X.   +15 more
europepmc   +1 more source